An updated review on primary signet-ring cell carcinoma of the urinary bladder and report of a case

References

• Wheeler JD, Hill WT. Adenocarcinoma involving the urinary bladder. Cancer. 1954;7:119–135.
   PubMed Web of Science ®Google Scholar
• Zaugloul MS, Nouh A, Nazmy M, et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol. 2006;24:13–20.
   PubMed Web of Science ®Google Scholar
• Thomas AA, Stephenson AJ, Campbell SC, et al. Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol. 2009;40:108–116.
   PubMed Web of Science ®Google Scholar
• Grignon DJ, Ro JY, Ayala AG, et al. Primary signet-ring cell carcinoma of the urinary bladder. Am J Clin Pathol. 1991;95:13–20.
   PubMed Web of Science ®Google Scholar
• Saphir O. Signet-ring cell carcinoma of the urinary bladder. Am J Pathol. 1955;31:223–231.
   PubMed Web of Science ®Google Scholar
• Holmang S, Borghede G, Johansson SL. Primary signet ring cell carcinoma of the bladder: a report on 10 cases. Scand J Urol Nephrol. 1997;31:145–148.
   PubMed Web of Science ®Google Scholar
• Busto Martin LA, Pais MJ, Dacal JG, et al. Signet-ring cell adenocarcinoma of the bladder: case series between 1990-2009. Arch Esp Urol. 2010;63:150–153.
   PubMedGoogle Scholar
• Akamatsu S, Takahashi A, Ito M, et al. Primary signet-ring cell carcinoma of the urinary bladder. Urology. 2010;75:615–618.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang FW. Clinical characteristics and outcomes of patients with primary signet-ring cell carcinoma of the urinary bladder. Urol Int. 2011;86:453–460.
   PubMed Web of Science ®Google Scholar
• Jakse G, Schneider HM, Jacobi GH. Urachal signet-ring cell carcinoma, a rare variant of vesical adenocarcinoma: incidence and pathological criteria. J Urol. 1978;120:764–766.
   PubMed Web of Science ®Google Scholar
• Blute ML, Segura JW, Patterson DE, et al. Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer. J Urol. 1989;141:1298–1301.
   PubMed Web of Science ®Google Scholar
• Fiter L, Gimeno F, Martin L, et al. Signet-ring cell adenocarcinoma of bladder. Urology. 1993;41:30–33.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang F, Kessinger A. The impact of signet-ring cell carcinoma histology on bladder cancer outcome. World J Urol. 2012;30:777–783.
   PubMed Web of Science ®Google Scholar
• Hamakawa T, Kojima Y, Naiki T, et al. Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined s-1 and Cisplatin adjuvant chemotherapy. Case Rep Urol. 2013;2013:915874.
   PubMedGoogle Scholar
• Kondo A, Ogisu B, Mitsuya H. Signet-ring cell carcinoma involving the urinary bladder. Report of a case and review of 21 cases. Urol Int. 1981;36:373–379.
   PubMed Web of Science ®Google Scholar
• Choi H, Lamb S, Pintar K, et al. Primary signet-ring cell carcinoma of the urinary bladder. Cancer 1984;53:1985–1990.
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours. Eur Urol. 2016;70:106–119.
   PubMed Web of Science ®Google Scholar
• Braun EV, Ali M, Fayemi AO, et al. Primary signet-ring cell carcinoma of the urinary bladder: review of the literature and report of a case. Cancer. 1981;47:1430–1435.
   PubMed Web of Science ®Google Scholar
• Bernstein SA, Reuter VE, Carroll PR, et al. Primary signet-ring cell carcinoma of urinary bladder. Urology. 1988;31:432–436.
   PubMed Web of Science ®Google Scholar
• Erdogru T, Kilicaslan I, Esen T, et al. Primary signet ring cell carcinoma of the urinary bladder. Review of the literature and report of two cases. Urol Int. 1995;55:34–37.
   PubMed Web of Science ®Google Scholar
• El Ammari JE, Ahsaini M, Riyach O, et al. Primary signet-ring cell carcinoma of the urinary bladder successfully managed with cisplatin and gemcitabine: a case report. J Med Case Rep. 2013;7:37
   PubMedGoogle Scholar
• Hirano Y, Suzuki K, Fujita K, et al. Primary signet ring cell carcinoma of the urinary bladder successfully treated with intra-arterial chemotherapy alone. Urology. 2002;59:601
   PubMedGoogle Scholar
• DeMay RM, Grathwohl MA. Signet-ring-cell (colloid) carcinoma of the urinary bladder. Cytologic, histologic and ultrastructural findings in one case. Acta Cytol. 1985;29:132–136.
   PubMed Web of Science ®Google Scholar
• Gopalan V, Smith RA, Ho YH, et al. Signet-ring cell carcinoma of colorectum-current perspectives and molecular biology. Int J Colorectal Dis. 2011;26:127–133.
   PubMed Web of Science ®Google Scholar
• Singh J, Zherebitskiy V, Grynspan D, et al. Metastatic signet ring cell adenocarcinoma of the bladder: responsive to treatment?. Can Urol Assoc J. 2012;6:E15–E19.
   PubMed Web of Science ®Google Scholar
• Terada T. Primary pure signet-ring cell adenocarcinoma of the urinary bladder: a report of three cases with an immunohistochemical study. Med Oncol. 2012;29:2866–2869.
   PubMed Web of Science ®Google Scholar
• el-Mekresh MM, el-Baz MA, Abol-Enein H, et al. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol. 1998;82:206–212.
   PubMedGoogle Scholar
• Yamamoto S, Ito T, Akiyama A, et al. Primary signet-ring cell carcinoma of the urinary bladder inducing renal failure. Int J Urol. 2001;8:190–193.
   PubMed Web of Science ®Google Scholar
• Gaurav K, Fitch J, Panda M. Increased frequency and nocturia in a middle aged male may not always be due to benign prostatic hypertrophy: a case report. Cases J. 2009;2:9274.
   PubMedGoogle Scholar
• Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. UICC International Union against Cancer. 7th ed. Oxford: ULCC; 2009.
   Google Scholar
• Hughes MJ, Fisher C, Sohaib SAA. Imaging features of primary nonurachal adenocarcinoma of the bladder. AJR Am J Roentgenol 2004;183:1397–1401.
   PubMed Web of Science ®Google Scholar
• Ponz M, Luzuriaga J, Robles JE, et al. Primary signet-ring cell carcinoma of the urinary bladder (linitis plastica). Eur Urol. 1985;11:212–214.
   PubMed Web of Science ®Google Scholar
• Torenbeek R, Koot RA, Blomjous CE, et al. Primary signet-ring cell carcinoma of the urinary bladder. Histopathology 1996;28:33–40.
   PubMed Web of Science ®Google Scholar
• Pugashetti N, Yap SA, Lara PN Jr, et al. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumor. Cuaj. 2015;9:E204–E207.
   Google Scholar
• Romics I, Szekely E, Szendroi A. Signet-ring cell carcinoma arising from the urinary bladder. Can J Urol. 2008;15:4266–4268.
   PubMed Web of Science ®Google Scholar
• Reddy K, Moore J, Girdler B, et al. Multidisciplinary management of primary signet-ring cell adenocarcinoma of the urinary bladder and the specific role of adjuvant radiotherapy. J Radiat Oncol. 2013;2:225–230.
   Google Scholar
• Cobo-Dols M, Alcaide J, Gutiérrez V, et al. Primary signet-ring cell adenocarcinoma of the urinary bladder: a case report. Oncología (Barc). 2006;29:177–180.
   Google Scholar
• Michels J, Barbour S, Cavers D, et al. Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature. Can Urol Assoc J. 2010;4:E55–E57.
   PubMedGoogle Scholar
• Ota T, Shimazui T, Hinotsu S. Primary signet ring cell carcinoma of the bladder effectively treated with intra-arterial chemotherapy and radiation therapy: a case report. Nishinihon J Urol. 1995;57:1019–1023.
   Google Scholar
• Witjes JA, Lebret T, Compérat EM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017;71:462–475.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al, editors. SEER cancer statistics review, 1975 -2014. Bethesda (MD): National Cancer Institute. Available from: https://seer.cancer.gov/csr/1975_2014/. Based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
   Google Scholar
• Nigwekar P, Tamboli P, Amin M, et al. Plasmacytoid urothelial carcinoma: detailed analysis of morphology with clinicopathologic correlation in 17 cases. Am J Surg Pathol. 2009;33:417–424.
   PubMed Web of Science ®Google Scholar
• Amin A, Tickoo S. Diagnostic Pathology: genitourinary. 2nd ed. Toronto: Elsevier; 2016.
   Google Scholar
• Knollman H, Godwin JL, Jain R, et al. Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Ther Adv Urol. 2015;7:312–330.
   PubMed Web of Science ®Google Scholar
• Cabibi D, Calascibetta A, Aragona F, et al. Differing expression of metalloprotease and of adhesion molecules in signet-ring cell and intestinal colorectal carcinoma. Anticancer Res. 2009;29:4417–4422.
   PubMed Web of Science ®Google Scholar
• Lim MG, Adsay NV, Grignon DJ, et al. E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma. Mod Pathol. 2011;24:241–247.
   PubMed Web of Science ®Google Scholar
• Loskog A, Ninalga C, Paul-Wetterberg G, et al. Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol. 2007;177:353–358.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Et Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461.
   PubMed Web of Science ®Google Scholar